{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:19:55Z","timestamp":1761898795134,"version":"build-2065373602"},"reference-count":4,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clinre.2024.102286","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T12:18:19Z","timestamp":1706012299000},"page":"102286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aspirin for non alcoholic fatty liver disease: Promising but inconclusive\u2013A letter to the editor"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1905-2299","authenticated-orcid":false,"given":"Hafiz Muhammad Sohaib","family":"Hayat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2024.102286_bib0001","unstructured":"Simon T.G. Aspirin in adults with nonalcoholic fatty liver disease [Internet]. clinicaltrials.gov; 2023 Aug [cited 2023 Jan 1]. Report No.: NCT04031729. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04031729."},{"key":"10.1016\/j.clinre.2024.102286_bib0002","unstructured":"Medscape [Internet]. [cited 2023 Nov 21]. Low-Dose Aspirin Reduces Liver Fat, Inflammation Markers. Available from: https:\/\/www.medscape.com\/viewarticle\/998550."},{"issue":"10","key":"10.1016\/j.clinre.2024.102286_bib0003","doi-asserted-by":"crossref","first-page":"e0268","DOI":"10.1097\/HC9.0000000000000268","article-title":"Aspirin is associated with a reduced incidence of liver disease in men","volume":"7","author":"Vell","year":"2023","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.clinre.2024.102286_bib0004","doi-asserted-by":"crossref","first-page":"G446","DOI":"10.1152\/ajpgi.00238.2021","article-title":"Angiotensin receptor blocker alleviates liver fibrosis by altering the mechanotransduction properties of hepatic stellate cells","volume":"322","author":"Huang","year":"2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221074012400007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221074012400007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:38Z","timestamp":1761896138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221074012400007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":4,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S221074012400007X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102286","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin for non alcoholic fatty liver disease: Promising but inconclusive\u2013A letter to the editor","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102286"}}